Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000
Debt
Debt-to-Equity Ratio3.22
Current Ratio5.54
Quick Ratio5.01
Price-To-Earnings
Trailing P/E Ratio-191.96
Forward P/E Ratio-883.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$463.77 million
Price / Sales11.23
Cash FlowN/A
Price / CashN/A
Book Value$2.72 per share
Price / Book32.46
Profitability
EPS (Most Recent Fiscal Year)($0.46)
Net Income$-26,830,000.00
Net Margins-3.47%
Return on Equity-11.91%
Return on Assets-2.32%
Miscellaneous
Employees857
Outstanding Shares59,000,000
Market Cap$5.13 billion
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, August, 2nd. The medical instruments supplier reported ($0.03) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.10. The medical instruments supplier earned $124.26 million during the quarter, compared to analyst estimates of $132.89 million. Insulet had a negative net margin of 3.47% and a negative return on equity of 11.91%. Insulet's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.13) earnings per share. View Insulet's Earnings History.
When is Insulet's next earnings date?
What price target have analysts set for PODD?
17 Wall Street analysts have issued 1 year price objectives for Insulet's stock. Their predictions range from $65.00 to $115.00. On average, they anticipate Insulet's stock price to reach $91.6875 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price. View Analyst Price Targets for Insulet.
What is the consensus analysts' recommendation for Insulet?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.
What are Wall Street analysts saying about Insulet stock?
Here are some recent quotes from research analysts about Insulet stock:
- 1. According to Zacks Investment Research, "Insulet exited the second-quarter 2018 on a mixed note. We are encouraged by the year-over-year improvement in net loss and revenues on solid uptake of Omnipod system in the United States. Expanding global customer base also drove revenues. Furthermore, expanding gross margin buoys optimism. We are also upbeat about Insulet’s solid progress with respect to its four-pillar strategy. Further, the receipt of FDA nod for the company’s Omnipod DASH Insulin Management System boosts investor confidence. Insulet has been outperforming its industry over the past year. Meanwhile, management expects the shifting to direct operations in Europe to continue to mar international revenues. Moreover, Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates." (8/17/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on PODD following the announcement that the company has secured two new OUS distributor partnerships with Theras Group (Italy) and Nordic Infucare (Nordic countries) effective July 1, 2018. Both distributors will provide sales, marketing, and customer support in their respective regions. We are encouraged to see PODD not only executing on OUS transition milestones but securing experienced medical device distributors in OUS countries. We believe the market exit by JNJ/Animas has created a unique opportunity for pump players – basically everyone ex Medtronic – to step into existing distribution/service networks who were left looking for new products when JNJ announced it was shuttering Animas. Thus, while not underestimating the resources required to build out an OUS commercial organization, the news of these two partnerships leaves us incrementally confident in Insulet’s ability to facilitate a smooth OUS transition." (5/2/2018)
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI) and Irhythm Technologies (IRTC).
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
- Ms. Shacey Petrovic, Pres & COO (Age 44)
- Mr. Michael L. Levitz, Sr. VP, CFO & Treasurer (Age 44)
- Mr. Charles Alpuche, Exec. VP & Chief Operations Officer (Age 58)
- Dr. Aiman Abdel-Malek, Exec. VP & Chief Technology Officer (Age 60)
Has Insulet been receiving favorable news coverage?
Media coverage about PODD stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insulet earned a news impact score of 0.20 on Accern's scale. They also assigned media headlines about the medical instruments supplier an impact score of 47.25 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Insulet.
Who are Insulet's major shareholders?
Insulet's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.82%), Frontier Capital Management Co. LLC (3.52%), Fred Alger Management Inc. (3.16%), Renaissance Technologies LLC (1.38%), OppenheimerFunds Inc. (1.34%) and KAMES CAPITAL plc (0.95%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, James C Mullen, Jessica Hopfield, John A Fallon, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan, Regina O Sommer and Shacey Petrovic. View Institutional Ownership Trends for Insulet.
Which institutional investors are selling Insulet stock?
PODD stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Schwab Charles Investment Management Inc., Fred Alger Management Inc., Columbus Circle Investors, American Century Companies Inc., Bank of New York Mellon Corp and Waddell & Reed Financial Inc.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, John A Fallon, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.
Which institutional investors are buying Insulet stock?
PODD stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, OppenheimerFunds Inc., Paloma Partners Management Co, Cubist Systematic Strategies LLC, Osterweis Capital Management Inc., LMR Partners LLP, FMR LLC and State Board of Administration of Florida Retirement System. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $88.30.
How big of a company is Insulet?
Insulet has a market capitalization of $5.13 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.
How can I contact Insulet?
Insulet's mailing address is 600 TECHNOLOGY PARK DRIVE SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (NASDAQ PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
